Thalidomide in patients with advanced multiple myeloma

The Hematology Journal : the Official Journal of the European Haematology Association
Ibrahim Yakoub-AghaIntergroupe Francophone du Myélome (IFM)

Abstract

Recently, a report has suggested the efficacy and safety of thalidomide in refractory multiple myeloma. In an attempt to assess the efficacy and tolerance of thalidomide in advanced multiple myeloma (on behalf of the Intergroupe Franchophone dy Myelome (IFM)), we report the preliminary experience of the IFM with this drug. Patients with advanced multiple myeloma (n=27) were treated with an oral dose of thalidomide (median 400 mg/day). At the start of treatment, all patients had active disease and 20 patients had received at least one autologous transplantation. Median follow-up was 105 days from the first administration. The serum and/or urine levels of the M-component were reduced by at least 75% in four patients including one patient with a >90% reduction, by at least 50% in five patients and by at least 25% in three patients, giving a total response rate of 45% (12 out of 27 patients). Nine patients had stable disease and six patients had progressed disease. Short-term side-effects of thalidomide were generally moderate. This study confirms that thalidomide is an effective agent in patients with advanced myeloma.

Citations

Sep 19, 2006·European Journal of Haematology·M Teresa CibeiraJoan Bladé
Sep 5, 2007·Bone Marrow Transplantation·M S RaabK C Anderson
Jun 14, 2001·British Journal of Haematology·J BladéE Montserrat
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Jean-Luc Harousseau
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosP Panayiotidis
Jan 19, 2005·European Journal of Haematology·G DamajJ A Gastaut
May 7, 2003·International Journal of Hematology·Seema Singhal, Jayesh Mehta
Aug 29, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kamakshi V Rao
Jul 27, 2001·British Journal of Haematology·G BarosiM Marchetti
Apr 2, 2003·Expert Opinion on Pharmacotherapy·Andrea MessoriBenedetta Santarlasci
Jul 12, 2003·Leukemia & Lymphoma·Saad Habib Abdalla, Sarah Mahmoud
Jul 16, 2005·Hematology·Soon Thye Lim, Alexandra M Levine
Aug 14, 2015·Molecular Cancer Therapeutics·Shaunna L BeedieWilliam D Figg
Aug 11, 2011·Bulletin du cancer·Mathieu WémeauIbrahim Yakoub-Agha

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.